Breast Cancer Research and Treatment

, Volume 39, Issue 3, pp 335–341 | Cite as

Influence of plasma estrogen levels on the length of the disease-free interval in postmenopausal women with breast cancer

  • Per E. Lønning
  • Svein I. Helle
  • Dag C. Johannessen
  • Dagfinn Ekse
  • Herman Adlercreutz
Report

Summary

The influence of plasma estrogen levels on disease-free interval (time from primary treatment to first relapse, DFI) in breast cancer patients is not known. Any relation between plasma estrogens and the outcome in breast cancer patients may have implications considering use of hormone replacement therapy (HRT) in patients treated for breast cancer. We measured plasma estradiol (E2), estrone (E1), and estrone sulfate (E1S) in 92 postmenopausal women with breast cancer relapse and correlated plasma estrogen levels to the length of their disease-free interval (DFI1) and the length of the DFI in the subgroup of patients in whom this extended a time period of more than 2 years (DFI2). The length of DFI2 correlated negatively to plasma level of E1S (p < 0.025) and E2 (p < 0.05) and to the E2/E1 and E1S/E1 ratios (p < 0.05), while the length of DFI1 correlated negatively to plasma level of E1S (p < 0.025) and the E1S/E1 ratio (p < 0.005). We also analyzed for possible correlations between DFIs and plasma estrogen levels in subgroups based on tumor stage at diagnosis and previous therapy. In general, these subgroup analyses revealed negative correlations of statistical significance or borderline significance between the DFI1 and DFI2 and E2 and the E2/E1 ratio and non-significant negative correlations between plasma levels of E1S and DFI1 and DFI2. In particular, strong negative correlations between plasma estrogen levels and the length of DFI1 and DFI2 were found among patients responding to first line endocrine treatment for relapse and among patients with primar stage III tumors. Our findings suggest plasma E2 and E1S to stimulate the growth of micrometastases in patients treated for breast cancer.

Key words

breast cancer disease-free interval estrogens 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Beatson GT: On the treatment of inoperable cases of carcinoma of the mamma. Suggestions for a new method of treatment, with illustrative cases. Lancet 2: 104–107, 1896Google Scholar
  2. 2.
    Furr BJA, Jordan VC: The pharmacology and clinical uses of tamoxifen. Pharmac Ther 25: 127–205, 1984Google Scholar
  3. 3.
    Santen RJ, Manni A, Harvey H, Redmond C: Endocrine treatment of breast cancer in women. Endocrine Rev 11: 221–265, 1990Google Scholar
  4. 4.
    Jones AL, Powles TJ, Law M, Tidy A, Easton D, Coombes RC, Smith IE, McKinna JA, Nash A, Ford HT, Gazet JC: Adjuvant aminoglutethimide for postmenopausal patients with primary breast cancer: analysis at 8 years. J Clin Oncol 10: 1547–1552, 1992PubMedGoogle Scholar
  5. 5.
    Early Breast Cancer Trialist Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Part 1. Lancet 339: 1–15, 1992Google Scholar
  6. 6.
    Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, Ernster VL, Cummings SR: Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 117: 1016–1037, 1992PubMedGoogle Scholar
  7. 7.
    Cobleigh MA, Berris RF, Bush T, Davidson NE, Robert NJ, Sparano JA, Tormey DC, Wood WC: Estrogen replacement therapy in breast cancer survivors. J Am Med Assoc 272: 540–545, 1994Google Scholar
  8. 8.
    Toniolo PG, Levitz M, Zeleniuch-Jacquotte A, Banerjee S, Koenig KL, Shore RE, Strax P, Pasternack BS: A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J Natl Cancer Inst 87: 190–197, 1995PubMedGoogle Scholar
  9. 9.
    Rose C, Theilade K, Boesen E, Salimtschik M, Dombernowsky P, Brünner N, Kjaer M, Mouridsen HT: Treatment of advanced breast cancer with tamoxifen: evaluation of the dose-response relationship at two dose levels. Breast Cancer Res Treat 2: 395–400, 1982Google Scholar
  10. 10.
    Lønning PE, Helle S-I, Johannessen DC, Adlercreutz H, Lien EA, Tally M, Ekse D, Fotsis T, Anker GB, Hall K: Relations between sex hormones, sex hormone binding globulin, insulin-like growth factor-I and insulin-like growth factor binding protein-1 in postmenopausal breast cancer patients. Clin Endocrinol 42: 23–30, 1995Google Scholar
  11. 11.
    Fotsis T, Adlercreutz H: The multicomponent analysis of oestrogens in urine by ion exchange chromatography GCMS. I. Quantitation of oestrogens after initial hydrolysis of conjugates. J Steroid Biochem 28: 203–213, 1987PubMedGoogle Scholar
  12. 12.
    Adlercreutz H, Gorbach SL, Goldin BR, Woods MN, Dwyer JT, Hämäläinen E: Estrogen metabolism and excretion in oriental and caucasian women. J Natl Cancer Inst 86: 1076–1082, 1994PubMedGoogle Scholar
  13. 13.
    Lønning PE, Lien EA, Lundgren S, Kvinnsland S: Clinical pharmacokinetics of endocrine agents used in advanced breast cancer. Clin Pharmacokinet 22: 327–358, 1992PubMedGoogle Scholar
  14. 14.
    Fracchia AA, Farrow JH, DePalo AJ, Connolly DP, Huvos AG: Castration for primary inoperable or recurrent breast carcinoma. Surg Gyn Obstet 128: 1226–1234, 1969Google Scholar
  15. 15.
    Høst H, Lund E: Age as a prognostic factor in breast cancer. Cancer 57: 2217–2221, 1986PubMedGoogle Scholar
  16. 16.
    Gambrell DR: Proposal to decrease the risk and improve the prognosis in breast cancer. Am J Obstet Gynecol 150: 119–128, 1984PubMedGoogle Scholar
  17. 17.
    Vassilopoulou-Sellin R, Theriault RL: Randomized prospective trial of estrogen-replacement therapy in women with a history of breast cancer. J Natl Cancer Inst Monogr 16: 153–159, 1994PubMedGoogle Scholar
  18. 18.
    Langlands AO, Pocock SJ, Kerr GR, Gore SM: Long-term survival of patients with breast cancer: a study of the curability of the disease. Brit Med J 2: 1247–1251, 1979PubMedGoogle Scholar
  19. 19.
    Eberlein T, Simon R, Fisher S, Lippman ME: Height, weight, and risk of breast cancer relapse. Breast Cancer Res Treat 5: 81–86, 1985PubMedGoogle Scholar
  20. 20.
    Santner SJ, Feil PD, Santen RJ:In situ estrogen production via the estrone sulfatase pathway in breast tumors: relative importance versus the aromatase pathway. J Clin Endocrinol Metab 59: 29–33, 1984PubMedGoogle Scholar
  21. 21.
    Tait GH, Newton CJ, Reed MJ, James VHT: Multiple forms of 17β-hydroxysteroid oxidoreductase in human breast tissue. J Molec Endocr 2: 71–80, 1989Google Scholar
  22. 22.
    Schneider J, Kinne D, Fracchia A, Pierce V, Anderson KE, Bradlow HL, Fishman J: Abormal oxidative metabolism of estradiol in women with breast cancer. Proc Natl Acad Sci USA 79: 3047–3051, 1982PubMedGoogle Scholar
  23. 23.
    De Nosaquo N: Androgens and estrogens in the treatment of disseminated mammary cancer. J Am Med Assoc 172: 1271–1283, 1960Google Scholar

Copyright information

© Kluwer Academic Publishers 1996

Authors and Affiliations

  • Per E. Lønning
    • 1
  • Svein I. Helle
    • 1
  • Dag C. Johannessen
    • 1
  • Dagfinn Ekse
    • 1
  • Herman Adlercreutz
    • 2
  1. 1.Department of OncologyHaukeland University HospitalBergenNorway
  2. 2.Department of Clinical ChemistryMeilahti Hospital, University of HelsinkiFinland

Personalised recommendations